The stock of OvaScience Inc (NASDAQ:OVAS) is a huge mover today! About 450,021 shares traded hands. OvaScience Inc (NASDAQ:OVAS) has declined 62.47% since April 27, 2016 and is downtrending. It has underperformed by 67.70% the S&P500.
The move comes after 5 months negative chart setup for the $116.94 million company. It was reported on Nov, 30 by Barchart.com. We have $3.04 PT which if reached, will make NASDAQ:OVAS worth $10.52M less.
Analysts await OvaScience Inc (NASDAQ:OVAS) to report earnings on February, 23. They expect $-0.58 earnings per share, up 23.68% or $0.18 from last year’s $-0.76 per share. After $-0.54 actual earnings per share reported by OvaScience Inc for the previous quarter, Wall Street now forecasts 7.41% negative EPS growth.
OvaScience Inc (NASDAQ:OVAS) Ratings Coverage
Out of 5 analysts covering OvaScience (NASDAQ:OVAS), 1 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 20% are positive. OvaScience has been the topic of 9 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The company was downgraded on Monday, January 25 by Oppenheimer. The stock has “Market Perform” rating given by Leerink Swann on Monday, November 9. As per Tuesday, September 29, the company rating was downgraded by JMP Securities. The firm has “Outperform” rating by Leerink Swann given on Friday, August 14. The stock of OvaScience Inc (NASDAQ:OVAS) earned “Underperform” rating by Credit Suisse on Thursday, January 21. The stock of OvaScience Inc (NASDAQ:OVAS) has “Outperform” rating given on Wednesday, October 21 by Oppenheimer. The stock of OvaScience Inc (NASDAQ:OVAS) has “Outperform” rating given on Wednesday, September 30 by Oppenheimer. On Tuesday, August 11 the stock rating was maintained by Wedbush with “Outperform”.
According to Zacks Investment Research, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.14 in 2016 Q2. Its down 2.23, from 3.37 in 2016Q1. The ratio dived, as 7 funds sold all OvaScience Inc shares owned while 12 reduced positions. 17 funds bought stakes while 47 increased positions. They now own 51.93 million shares or 132.78% more from 22.31 million shares in 2016Q1.
Pnc Group holds 0% or 116 shares in its portfolio. Of Vermont holds 0% or 1,465 shares in its portfolio. Great West Life Assurance Can has 3,500 shares for 0% of their US portfolio. Moreover, Blackrock Inc has 0% invested in OvaScience Inc (NASDAQ:OVAS) for 5,792 shares. Rhumbline Advisers has 0% invested in the company for 43,990 shares. Fny Managed Accounts Ltd Liability reported 40,000 shares or 0% of all its holdings. Fuller & Thaler Asset Mngmt owns 216,153 shares or 0.02% of their US portfolio. Millennium Ltd Liability accumulated 136,569 shares or 0% of the stock. Morgan Stanley holds 0% or 23,925 shares in its portfolio. Art Advisors Ltd holds 0.01% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 33,928 shares. Blackrock Advisors Ltd Co reported 13,472 shares or 0% of all its holdings. Schwab Charles Management last reported 0% of its portfolio in the stock. Moreover, Deutsche National Bank Ag has 0% invested in OvaScience Inc (NASDAQ:OVAS) for 14,084 shares. Parametric Portfolio Associate Llc accumulated 0% or 39,431 shares. Howland Capital Mngmt Limited Liability accumulated 117,560 shares or 0.06% of the stock.
Another recent and important OvaScience Inc (NASDAQ:OVAS) news was published by Nasdaq.com which published an article titled: “Can OvaScience (OVAS) Keep the Earnings Streak Alive This Quarter?” on November 30, 2016.
OVAS Company Profile
OvaScience, Inc., incorporated on April 5, 2011, is a global fertility company. The Firm is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is specifically designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization (IVF) process to supplement the existing mitochondria.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.